Yazar "Ürün, Yüksel" için listeleme
-
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin (Elsevier, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare ... -
Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Akar, Emre; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek; Kılıçkap, Saadettin (Lippincott Williams & Wilkins, 2023)... -
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study
Yıldız, Birol; Küçükarda, Ahmet; Gökyer, Ali; Demiray, Atike Gökçen; Paydaş, Semra; Aral, İpek Pınar; Gümüşay, Özge; Bilici, Ahmet; Akdeniz, Nadiye; Bahçeci, Aykut; Demir, Hacer; Esin, Ece; Üyetürk, Ümmügül; Ökten, İlker Nihat; Ertürk, İsmail; Türk, Hacı Mehmet; Topaloğlu, Ulaş Serkan; Başoğlu, Tuğba; Turhal, Nazım Serdar; Yeşil Çınkır, Havva; Menekşe, Serkan; Çakmak, Yağmur; Ürün, Yüksel; Acar, Ramazan; Kut, Engin; Dal, Pınar; Sakalar, Teoman; Aktepe, Oktay Halit; Karadurmuş, Nuri (Imprimatur Publications, 2020)Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.Methods: In our study, 612 seminomatous ... -
Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Akar, Emre; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek; Karadurmuş, Nuri; Kılıçkap, Saadettin (CIG Media Group, 2023)This 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly ... -
Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Erman, Mustafa; Ürün, Yüksel; Karadurmuş, Nuri; Akar, Emre; Kılıçkap, Saadettin (Lippincott Williams & Wilkins, 2022)Background: Anti-tumor activity and manageable safety profile of immune checkpoint blockade therapies (ICT) have been demonstrated in previous clinical trials in patients with metastatic urothelial carcinoma. To the best ... -
Merkel cell carcinoma in Turkey: A multicentric study
Yıldız, Fatih; Demirci, Umut; Küçükarda, Ahmet; Büyükşimşek, Mahmut; Sakalar, Teoman; Öztürk Topçu, Türkan; Aslan, Ferit; Tufan, Gülnihal; Aydın, Övgü; Turna, Hande; Akgül Babacan, Nalan; Başoğlu, Tugba; Kurt, Bediz; Yıldız, Birol; Eren, Tülay; Demiray, Atike Gökçen; Gümüşay, Özge; Arslan, Çağatay; Özdemir, Nuriye; Ürün, Yüksel; Baykara, Meltem; Turan, Nedim; Uysal, Mükremin; Bilici, Ahmet; Kavgacı, Halil; Çiçin, İrfan; Kılıçkap, Saadettin; Paydaş, Semra (Wolters Kluwer Medknow Publications, 2021)Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of ... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ... -
Predictive factor for lymph node metastasis in non-metastatic colorectal adenocarcinomas
Karcı, Ebru; Ürün, Yüksel; Köksoy, Elif Berna; Uçar, Gökhan; Bilgin, Burak; Yekedüz, Emre; Arslan, Çağatay; Alkan, Ali; Dede, İsa; Tuncay, Gülseren; Hocazade, Cemil; Yıldırım Özdemir, Nuriye; Şendur, Mehmet Ali Nahit; Utkan, Güngör; Yalçın, Bülent; Akbulut, Hakan (Kare Publishing, 2022)Objectives: To evaluate the predictive factors of lymph node involvement in non-metastatic colorectal adenocarcinomas (nmCRC). Methods: A total of 453 patients diagnosed with nmCRC were analyzed regarding T stage, ... -
Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
Göktaş Aydın, Sabin; Kavak, Engin Eren; Topçu, Atakan; Bayramgil, Ayberk; Akgül, Fahri; Kahraman, Seda; Aykan, Musa Barış; Altıntaş, Yunus Emre; Helvacı, Kaan; Ürün, Yüksel; Bilici, Ahmet; Şeker, Mesut (Association of Basic Medical Sciences of FBIH, 2023)Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin; Artaç, Mehmet (Springer Japan KK, 2021)Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer
Göktaş Aydın, Sabin; Çakan Demirel, Burçin; Bilici, Ahmet; Topçu, Atakan; Aykan, Musa Barış; Kahraman, Seda; Akbıyık, Ilgın; Atçı, Muhammed Mustafa; Ölmez, Ömer Fatih; Yaren, Arzu; Şendur, Mehmet Ali Nahit; Geredeli, Çağlayan; Şeker, Mesut; Ürün, Yüksel; Karadurmuş, Nuri; Aydın, Ahmet (Taylor & Francis Ltd, 2022)Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to ... -
The real-life efficacy of the second line treatment strategy in advanced pancreas cancer
Hızal, Mutlu; Şendur, Mehmet Ali Nahit; Bilgin, Burak; Karcı Güner, Ebru; Akıncı, Muhammed Bülent; Ergün, Yakup; Esin, Ece; Köksoy, Elif Berna; Sezer, Ahmet; Özdemir, Nuriye; Öksüzoğlu, Berna; Yalçın, Bülent; Utkan, Güngör; Ürün, Yüksel (Turkiye Klinikleri, 2022)ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options ...